FDA approves 1st immunotherapy drug to treat breast cancer

Health
FDA_Generic_Asthma_Inhaler_65644-159532.jpg88590397

FILE – This Oct. 14, 2015, file photo shows the Food and Drug Administration campus in Silver Spring, Md. The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The FDA on Wednesday, Jan. 30, 2019, approved Mylan’s version in three strengths for ages 4 and up. (AP Photo/Andrew […]

The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer.

Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It’s to be given with chemotherapy, the standard treatment.

Mount Sinai breast cancer specialist Dr. Amy Tiersten in New York called it “tremendously exciting news.”

Approved for two other cancers, Tecentriq works by boosting the immune system’s ability to spot and kill cancer cells.

In a study of 900 women, the benefits were modest. Those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone. The combo caused nerve pain, nausea and other side effects.

Tecentriq costs about $13,400 per month.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Trending Stories